Companies collaborate to set a new standard
for patient-centric digital clinical trials
BRUSSELS and PLEASANTON, Calif., May 23, 2023
/PRNewswire/ -- Veeva Systems (NYSE: VEEV) and UCB, a global
biopharmaceutical company, today announced a collaboration that
will focus on technology-driven solutions aimed at improving the
patient experience and trial efficiency. The collaboration will see
UCB adopt Veeva ePRO and Veeva eConsent, to provide a
patient-centric, digital experience to study participants and
actively influence the strategic direction of these and other
applications based on learnings. Together, Veeva and UCB aim to set
a new industry standard for digital clinical trials with multiple
applications that meet the unique needs of patients.
"The partnership between UCB and Veeva presents a significant
opportunity to drive progress in clinical study execution," said
Iris Loew-Friedrich, executive vice
president and chief medical officer at UCB. "By delivering digital
clinical trials, we reduce the burden on participants and sites,
improve trial accessibility, and ensure patients are at the heart
of everything we do."
Veeva ePRO simplifies the design, management, and completion of
electronic patient-reported outcomes (ePRO) with seamless data flow
among sponsors, sites, and patients. Veeva eConsent simplifies the
set-up, completion, and review of consent for patients, sites, and
study teams. Both applications are available to patients through
MyVeeva for Patients, which provides one point of access for all
their clinical trial actions, scheduling, and communications. Veeva
ePRO and Veeva eConsent are part of Veeva Vault Clinical Suite, a
set of integrated capabilities that simplify the technology
landscape of clinical trials for both clinical operations and
clinical data management.
"We're excited to partner with UCB to advance
patient-centric digital trials," said Veeva CEO Peter Gassner. "Their input will help advance
Veeva's approach to solutions that make digital trials work even
better for sponsors, sites, and patients."
Edwin Erckens, chief digital technology officer at UCB
added, "UCB's collaboration with Veeva is yet another proof
point of our ongoing effort to drive digital business
transformation. By leveraging our collective expertise, we can push
the boundaries of what technology can achieve to improve the
clinical trial process."
About UCB
UCB, Brussels,
Belgium (www.ucb.com) is a global biopharmaceutical company
focused on the discovery and development of innovative medicines
and solutions to transform the lives of people living with severe
diseases of the immune system or of the central nervous system.
With approximately 8700 people in approximately 40 countries, the
company generated revenue of € 5.5 billion in 2022. UCB is listed
on Euronext Brussels (symbol: UCB).
About Veeva Systems
Veeva is the global leader in
cloud software for the life sciences industry. Committed to
innovation, product excellence, and customer success, Veeva serves
more than 1,000 customers, ranging from the world's largest
biopharmaceutical companies to emerging biotechs. As a Public
Benefit Corporation, Veeva is committed to balancing the interests
of all stakeholders, including customers, employees, shareholders,
and the industries it serves. For more information,
visit veeva.com.
Veeva Forward-looking Statements
This release contains forward-looking statements regarding
Veeva's products and services and the
expected results or benefits from use of
our products and services. These statements are based on
our current expectations. Actual results could differ
materially from those provided in this release and we have no
obligation to update such statements. There are numerous
risks that have the potential to negatively impact
our results, including the risks and uncertainties disclosed
in our filing on Form 10-K for the fiscal year ended January 31, 2023, which you can
find here (a summary of risks which may impact our
business can be found on pages 9 and 10), and in our subsequent SEC
filings, which you can access at sec.gov.
Contact:
|
|
Jeremy
Whittaker
|
Scott
Fleming
|
Veeva
Systems
|
R&D Communications,
UCB
|
+49-695-095-5486
|
+447702777378
|
jeremy.whittaker@veeva.com
|
scott.fleming@ucb.com
|
|
|
Laurent
Schots
|
Corporate
Communications, UCB
|
+32.2.559.92.64
|
laurent.schots@ucb.com
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ucb-and-veeva-collaborate-to-advance-the-patient-experience-in-clinical-trials-301831754.html
SOURCE Veeva Systems